"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
| Descriptor ID |
D008727
|
| MeSH Number(s) |
D03.633.100.733.631.192.500
|
| Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 2 | 7 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 5 | 6 |
| 1999 | 0 | 3 | 3 |
| 2000 | 3 | 0 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 4 | 4 | 8 |
| 2006 | 4 | 2 | 6 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 4 | 6 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 6 | 7 |
| 2011 | 1 | 5 | 6 |
| 2012 | 1 | 4 | 5 |
| 2013 | 4 | 3 | 7 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 6 | 8 |
| 2016 | 1 | 5 | 6 |
| 2017 | 5 | 6 | 11 |
| 2018 | 7 | 3 | 10 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 2 | 4 | 6 |
| 2024 | 6 | 4 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
-
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. J Rheumatol. 2024 Nov 01; 51(11):1125-1134.
-
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
-
Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.
-
Methotrexate: Borrowed Hope for Persons With Knee Osteoarthritis? Ann Intern Med. 2024 Sep; 177(9):1271-1272.
-
Late-life dietary folate restriction reduces biosynthesis without compromising healthspan in mice. Life Sci Alliance. 2024 Oct; 7(10).
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct; 71(10):e31213.
-
Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non-target red blood cells of patients with Crohn's disease. Basic Clin Pharmacol Toxicol. 2024 Sep; 135(3):308-320.
-
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
-
Juvenile eosinophilic fasciitis: a single center case series. Pediatr Rheumatol Online J. 2024 Feb 24; 22(1):29.